Daina Graybosch
Stock Analyst at Leerink Partners
(0.85)
# 3,797
Out of 4,884 analysts
108
Total ratings
35.9%
Success rate
-10.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $24.55 | -51.12% | 1 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $10.18 | -11.59% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $80.93 | +47.04% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.32 | +51.52% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.92 | +237.84% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $67.16 | -41.93% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $24.76 | +81.74% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.56 | +2,422.07% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.12 | +792.86% | 7 | Jan 6, 2023 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.88 | +380.00% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $8.47 | +348.64% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.76 | +112.77% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $110.00 | +103.64% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.75 | +1,614.29% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.07 | +1,488.79% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.76 | +411.36% | 4 | Feb 25, 2022 |
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $24.55
Upside: -51.12%
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $10.18
Upside: -11.59%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $80.93
Upside: +47.04%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.32
Upside: +51.52%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.92
Upside: +237.84%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $67.16
Upside: -41.93%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $24.76
Upside: +81.74%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.56
Upside: +2,422.07%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.12
Upside: +792.86%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.88
Upside: +380.00%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $8.47
Upside: +348.64%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.76
Upside: +112.77%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $110.00
Upside: +103.64%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.75
Upside: +1,614.29%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.07
Upside: +1,488.79%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.76
Upside: +411.36%